The trials will be carried out with one of Juno’s investigational CD19-directed chimeric antigen receptor (CAR) T cell candidates and MedImmune’s investigational programed cell death ligand 1 (PD-L1)
The tablets are indicated to treat chronic hepatitis C, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen. The virus affects over 100 million
The open-label, multicenter, dose-escalation Phase I trial is designed to evaluate an intravenous (IV) formulation of marizomib in combination with bevacizumab (Avastin) in these patients. Patient enrollment is
GC Group is an Israeli pharmaceutical R&D firm engaged in development of several new generic drug products of different types. As part of the deal, GC Group will
The drug was granted orphan drug status under the US Orphan drug Act following a review by the FDA of a package of pre-clinical data submitted by the
MBX-8025 is a potent and selective peroxisome proliferator-activated receptor delta (PPARd) agonist currently being evaluated by the company in high unmet need and orphan diseases. Recently, MBX-8025 also
The anti-cancer agent is designed to treat relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted
Betaseron is a prescription medicine used to reduce the number of relapses in people with relapsing forms of MS, which includes people who have had their first symptoms
In the US, Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or who are
ROS1-positive NSCLC occurs in approximately 1% of NSCLC cases and it represents a particular molecular subgroup of NSCLC. The breakthrough therapy designation was based on a data from
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.